Global Cancer Tumor Profiling Market – Industry Trends and Forecast to 2029

9350
Present Value (M$)
2021
24440
Forecast Value (M$)
2029
12.75%
CAGR (%)

Data Bridge Market Research analyses that the cancer tumor profiling market is expected to undergo a CAGR of 12.75% during the forecast period. This indicates that the market value, which was USD 9.35 billion in 2021, would rocket up to USD 24.44 billion by 2029.

Main companies

  • Illumina
  • Inc. (US)
  • QIAGEN (Germany)
  • NeoGenomics Laboratories
  • Inc. (US)
  • HTG Molecular Diagnostics
  • Inc. (US)
  • Genomic Health Inc. (US)
  • Caris Life Sciences (US)
  • Helomics Corporation (US)
  • NanoString Technologies
  • Inc. (US)
  • Sysmex Corporation (Japan)
  • Ribomed Biotechnologies
  • Inc. (US)
  • Guardant Health
  • Inc. (US)
  • Foundation Medicine (US) Roche Diagnostics (Switzerland)
  • (US)
  • GenScript Biotech Corporation (China)
  • Tempus Labs (US)
  • Boreal Genomics Inc (Canada)
  • Perthera (US)
  • Agendia (US)
  • Omniseq (US)
  • Histogene X (Belgium)